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Locked Nucleic Acid (LNA) is a nucleic acid analogue with 
unprecedented binding affinity and excellent specificity toward 
complementary RNA and DNA oligonucleotides. The remark-
able properties of LNA have led to applications within various 
gene silencing strategies both in vitro and in vivo. In the present 
review, we highlight the uses of LNA for regulation of gene 
expression with emphasis on RNA targeting.
Introduction
Nucleic acid derivatives have gained a lot of interest for the 
treatment of many diseases, and the first oligonucleotide to enter 
the clinic was Vitravene®,1 an antisense oligonucleotide for the 
treatment of cytomegalovirus infection. The use of chemically 
modified nucleic acids is needed as naturally occurring DNA or 
RNA have some limitations like poor RNA binding affinity, inef-
ficient cellular uptake and very limited nuclease resistance. Among 
the numerous modifications known, LNA has shown broad useful-
ness within chemical biology.2-9
LNA: Structural Features and Key Properties
LNA (Fig. 1) contains a ribose ring which is locked by a 
O2'-C4'-methylene linkage, imposing conformational restriction 
to adopt an N-type sugar puckering.2-5,10 Structural investigation 
of LNA oligonucleotides by NMR spectroscopy revealed their 
similarities with natural nucleic acid duplexes, and confirmed the 
RNA mimicking structures adopted by LNA.11,12
LNA offers key properties needed for successful therapeutic 
exploitation of oligonucleotides, including (1) unprecedented 
binding affinity towards RNA (and DNA), (2) excellent base 
pairing specificity, (3) high bio-stability (resistance towards nucle-
olytic degradation, (4) low toxicity (at least for many LNA 
oligonucleotides) in animals and (5) convenient chemistry for 
manufacturing and modification.
LNA in Antisense Technologies
‘Antisense’ is a term normally used for single stranded nucleic 
acid based approaches that interfere with the processing of RNA 
in a sequence selective manner. For effective modulation of 
gene expression, the advantages of synthetic oligonucleotides are 
exploited through binding of antisense oligonucleotides (AONs) 
to a specific mRNA or pre-mRNA by Watson-Crick base pairing. 
Upon binding, the oligonucleotide can modulate RNA processing, 
inhibit translation, or promote degradation. Antisense-based gene 
silencing strategies using LNA-containing oligonucleotides have 
already been the topic of detailed reviews.9,13,14
LNA-antisense experiments have largely been focused on 
mRNA inhibition by RNase H recruitment, though non RNase 
H mechanisms have also been reported. These studies highlight 
a broad potential of LNA oligonucleotides for effective gene 
silencing both in vitro and in vivo. Recently, Jacobsen et al. for 
example showed that LNA AONs are effective inhibitors of HIV-1 
expression.15
DNAzymes are catalytically active DNA molecules that are 
able to cleave RNA in a sequence-specific manner after binding to 
complementary sequences. Studies conducted using LNA-modified 
DNAzymes, termed LNAzymes showed an enhanced efficiency of 
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Figure 1. Two representations of an LNA monomer. The structure is shown 
schematically to the left, whereas the structure and its locked sugar ring 
conformation is shown in three dimensions to the right.
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LNA Aptamers
Aptamers24-26 are short DNA or RNA oligonucleotide sequences 
which can bind tightly to a specific molecular target because of 
their ability to form three dimensional structures. The remarkable 
properties and applications of LNA oligonucleotides highlighted 
above substantiate the desire to explore aptamers composed of 
LNA-modified nucleotides to rival aptamers composed of unmodi-
fied RNA or DNA. Darfeuille et al. introduced LNA modification 
of an already selected RNA aptamer targeted to the TAR RNA 
element of HIV-1.27,28 Surface plasmon resonance (SPR) experi-
ments identified LNA/DNA mixmers binding to TAR RNA with 
a dissociation constant in the low nanomolar range. Schmidt et al. 
later described the capability of LNA nucleotides to improve the in 
vivo stability of aptamers.29 Further work showed that an aptamer 
modified with LNA nucleotides targeting the TAR RNA element 
of HIV-1 displayed good binding properties and competed with 
the viral protein Tat for binding to TAR.30 Furthermore, the same 
group later reported a TAR RNA aptamer as an LNA/2'-O-methyl 
RNA mixmer which displayed improved HIV-1 TAR element 
binding.31 All of these results underscore the desire to develop 
procedures to allow evolution of LNA aptamers by SELEX-
based32,33 processes.
Future Prospects
The remarkable properties of LNA with respect to high 
affinity and specificity make this analogue unique for appli-
cations in molecular biology research, biotechnology and 
RNA targeting. We believe that LNA constructs will be impor-
tant molecules as the prospects of nucleic acid based drugs will 
be realized. This is underlined by the recent reports on efficient 
miRNA targeting using LNA probes and the fact that LNA/
DNA mixmers have been forwarded into human clinical trails.34 
We are attempting to develop ways of evolving LNA-based 
aptamers and have recently published reports on enzymatic 
methods for synthesis of LNA containing oligonucleotides.35,36
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RNA cleavage.16 In line with previous findings, Jacobsen et al. 
reported efficient inhibition of HIV-1 expression by targeting 
LNAzymes to functionally selected binding sites,15 whereas 
targeting of miRNAs by using LNAzymes has recently been 
reported by Maiti and co-workers.17
RNA interference (RNAi) has been developed as a highly potent 
approach to knock down gene expression.18 RNAi mediated 
by small interfering RNAs (siRNAs) can target complemen-
tary mRNA and induce its degradation upon incorporation of 
the siRNA into the RNA-induced silencing complex (RISC). 
siRNAs themselves are candidates for incorporation of modi-
fied nucleotides for improved bio-stability and effective RNA 
targeting. In this direction, the use of LNA-modified siRNA, 
termed siLNA, has been investigated. Recently, Mook et al. 
evaluated the effect of LNA-modified siRNA both in vitro and 
in vivo.19 They showed that minimal LNA-modifications at 
the 3'-end of siRNAs are effective to stabilize the siRNA, and 
that multiple LNA-modifications may lead to decreased effi-
cacy in vitro and in vivo. The study also highlighted reduced 
off-target gene regulation when using LNA-modified siRNA 
(compared to the unmodified siRNA). Very recently, Bramsen et al. 
introduced a three stranded siRNA construct termed ‘small inter-
nally segmented interfering RNA’ (sisiRNA, Fig. 2) in which the 
antisense strand is complexed with two short sense strands of 
approximately 10–12 nt in length.20 In the sisiRNA approach 
only the antisense strand is functional as the nick completely 
eliminates unintended mRNA targeting by the sense strand. 
LNA nucleotides were incorporated to stabilize the sisiRNA 
constructs which proved efficient for gene silencing upon transfec-
tion into a H1299 lung carcinoma cell line.
MicroRNAs (miRNAs) constitute a class of short regulatory 
RNAs (~22 n) that control gene expression post-transcriptionally 
during development, differentiation and metabolism.21,22 Similar 
to classical AONs developed for the inhibition of coding RNAs, 
synthetic oligonucleotides are the only rational approach for 
specific inhibition of individual miRNAs and therefore have the 
potential to be developed into an important new class of miRNA 
targeting drugs. Elmén et al. have recently described effective 
miRNA silencing in non-human primates by short LNA-modified 
oligonucleotides (LNA antimiRs; LNA/DNA mixmers) designed 
to target liver-expressed miR-122.23
Figure 2. Schematic representations of siRNA and sisiRNA constructs. In a classical siRNA construct, the sense strand complementary to the antisense 
strand is single stranded. In a sisiRNA construct, a nick has been introduced in the sense strand which is therefore constituted by two separate short 
strands complementary to the antisense strand. Both constructs are depicted with two nucleotide 3'-overhangs and with a shortened duplex region; 
this in typical siRNA and sisiRNA constructs contains 19 base pairs.
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